Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

High doses of Δ9-tetrahydrocannabinol might impair irinotecan chemotherapy: A review of potentially harmful interactions (CROSBI ID 280705)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kopjar, Nevenka ; Fuchs, Nino ; Brčić Karačonji, Irena ; Žunec, Suzana ; Katić, Anja ; Kozina, Goran ; Lucić Vrdoljak, Ana High doses of Δ9-tetrahydrocannabinol might impair irinotecan chemotherapy: A review of potentially harmful interactions // Clinical drug investigation, 40 (2020), 9; 775-787. doi: 10.1007/s40261-020-00954-y

Podaci o odgovornosti

Kopjar, Nevenka ; Fuchs, Nino ; Brčić Karačonji, Irena ; Žunec, Suzana ; Katić, Anja ; Kozina, Goran ; Lucić Vrdoljak, Ana

engleski

High doses of Δ9-tetrahydrocannabinol might impair irinotecan chemotherapy: A review of potentially harmful interactions

This review proposes the hypothesis that the effectiveness of irinotecan chemotherapy might be impaired by high doses of concomitantly administered Δ9-tetrahydrocannabinol (THC). The most important features shared by irinotecan and THC, which might represent sources of potentially harmful interactions are: first pass hepatic metabolism mediated by cytochrome P-450 (CYP) enzyme CYP3A4 ; glucuronidation mediated by uridine diphosphate glycosyltransferase (UGT) enzymes, isoforms 1A1 and 1A9 ; transport of parent compounds and their metabolites via canalicular ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 ; enterohepatic recirculation of both parent compounds which leads to an extended duration of their pharmacological effects ; possible competition for binding to albumin ; butyrylcholinesterase (BChE) inhibition by THC which might impair the conversion of parent irinotecan into the SN-38 metabolite ; mutual effects on mitochondrial dysfunction and induction of oxidative stress ; potentiation of hepatotoxicity ; potentiation of genotoxicity and cytogenetic effects leading to genome instability ; possible neurotoxicity ; and effects on bilirubin. The controversies associated with the use of highly concentrated THC preparations with irinotecan chemotherapy are also discussed. Despite all of the limitations, the body of evidence provided here could be considered relevant for human risk assessments and calls for concern in cases when irinotecan chemotherapy is accompanied by preparations rich in THC.

Tetrahydrocannabinol ; irinotecan ; drug-drug interaction, illicit THC preparations

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

40 (9)

2020.

775-787

objavljeno

1173-2563

1179-1918

10.1007/s40261-020-00954-y

Povezanost rada

Farmacija, Kliničke medicinske znanosti, Temeljne medicinske znanosti

Poveznice
Indeksiranost